Biomerica (BMRA) Competitors $3.15 -0.09 (-2.78%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$3.32 +0.18 (+5.56%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. KPTI, AKTX, MAAQ, XLO, MDCX, DYAI, SNYR, ESLA, RANI, and SLGLShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Karyopharm Therapeutics (KPTI), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Xilio Therapeutics (XLO), Medicus Pharma (MDCX), Dyadic International (DYAI), Synergy CHC (SNYR), Estrella Immunopharma (ESLA), Rani Therapeutics (RANI), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors Karyopharm Therapeutics Akari Therapeutics Mana Capital Acquisition Xilio Therapeutics Medicus Pharma Dyadic International Synergy CHC Estrella Immunopharma Rani Therapeutics Sol-Gel Technologies Biomerica (NASDAQ:BMRA) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings. Does the media refer more to BMRA or KPTI? In the previous week, Karyopharm Therapeutics had 2 more articles in the media than Biomerica. MarketBeat recorded 2 mentions for Karyopharm Therapeutics and 0 mentions for Biomerica. Biomerica's average media sentiment score of 0.00 equaled Karyopharm Therapeutics'average media sentiment score. Company Overall Sentiment Biomerica Neutral Karyopharm Therapeutics Neutral Which has higher earnings and valuation, BMRA or KPTI? Biomerica has higher earnings, but lower revenue than Karyopharm Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.41M1.48-$5.98M-$2.32-1.36Karyopharm Therapeutics$145.24M0.23-$76.42M-$13.26-0.30 Do institutionals & insiders believe in BMRA or KPTI? 22.3% of Biomerica shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 15.0% of Biomerica shares are owned by insiders. Comparatively, 3.0% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate BMRA or KPTI? Karyopharm Therapeutics has a consensus target price of $37.40, indicating a potential upside of 851.65%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Karyopharm Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is BMRA or KPTI more profitable? Karyopharm Therapeutics has a net margin of -43.99% compared to Biomerica's net margin of -85.42%. Karyopharm Therapeutics' return on equity of 0.00% beat Biomerica's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-85.42% -85.90% -61.06% Karyopharm Therapeutics -43.99%N/A -35.95% Which has more risk & volatility, BMRA or KPTI? Biomerica has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. SummaryKaryopharm Therapeutics beats Biomerica on 11 of the 15 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.25M$2.46B$5.49B$9.52BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-1.368.9728.7823.81Price / Sales1.48437.65372.2066.04Price / CashN/A157.7635.4557.96Price / Book1.014.838.275.54Net Income-$5.98M$31.62M$3.25B$259.28M7 Day Performance-19.44%-5.28%-3.70%-4.64%1 Month Performance-2.48%4.38%4.34%4.41%1 Year Performance42.92%-2.49%25.90%17.95% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.2073 of 5 stars$3.15-2.8%N/A+31.3%$8.25M$5.41M-1.3660Gap DownKPTIKaryopharm Therapeutics3.4275 of 5 stars$4.23-3.2%$37.40+784.0%-71.6%$36.56M$145.24M-0.32380Upcoming EarningsGap DownAKTXAkari Therapeutics2.6884 of 5 stars$1.11-1.8%$5.00+350.5%-73.1%$35.72MN/A0.009MAAQMana Capital AcquisitionN/A$4.39-4.2%N/A+875.0%$35.65MN/A0.001Gap DownXLOXilio Therapeutics3.2315 of 5 stars$0.68-0.3%$4.00+488.2%-31.6%$35.21M$6.34M-0.8170News CoverageMDCXMedicus Pharma2.4642 of 5 stars$2.58+5.7%$23.50+810.9%N/A$35.02MN/A-2.22N/AUpcoming EarningsDYAIDyadic International2.0793 of 5 stars$1.14+2.7%$6.00+426.3%-25.6%$34.30M$3.49M-5.707News CoveragePositive NewsSNYRSynergy CHC3.875 of 5 stars$3.68-1.1%$10.00+171.7%+3,260.0%$33.82M$34.83M0.0040Trending NewsESLAEstrella Immunopharma2.9551 of 5 stars$0.93+1.0%$16.00+1,622.3%-51.2%$33.60MN/A-3.57N/ARANIRani Therapeutics1.757 of 5 stars$0.52-5.6%$7.33+1,310.3%-80.6%$32.81M$1.03M-0.52110Negative NewsUpcoming EarningsShort Interest ↑SLGLSol-Gel Technologies1.8078 of 5 stars$11.45-4.7%$40.00+249.3%+209.5%$31.95M$11.54M-2.4450Gap Down Related Companies and Tools Related Companies Karyopharm Therapeutics Alternatives Akari Therapeutics Alternatives Mana Capital Acquisition Alternatives Xilio Therapeutics Alternatives Medicus Pharma Alternatives Dyadic International Alternatives Synergy CHC Alternatives Estrella Immunopharma Alternatives Rani Therapeutics Alternatives Sol-Gel Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BMRA Stock Alerts